Q4 2025 Biotricity Inc Earnings Call Transcript
Key Points
- Biotricity Inc (BTCY) achieved a 16.5% year-over-year revenue increase in the fourth quarter, reaching $3.7 million.
- The company expanded its Cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's TensorFlow, enhancing diagnostic accuracy and patient outcomes.
- Biotricity Inc (BTCY) secured strategic alliances with three major group purchasing organizations, providing access to approximately 90% of U.S. hospitals.
- The company achieved positive adjusted EBITDA of $438,000 in the last quarter of fiscal 2025, indicating progress towards profitability.
- Biotricity Inc (BTCY) received regulatory approval in Saudi Arabia, aligning with its strategy to expand internationally and improve patient outcomes.
- Biotricity Inc (BTCY) reported a net loss attributable to common stockholders of $11.9 million for the fiscal year ended March 31, 2025.
- The sales cycles for new partnerships and pilots with GPOs are lengthy, potentially delaying revenue realization.
- Despite improvements, the company still faces challenges in achieving profitability, with a net loss per share of $0.555 for the fiscal year.
- The company lacks in-house expertise to monetize its extensive data set, which could be a missed opportunity for additional revenue.
- Biotricity Inc (BTCY) anticipates that international market revenue contributions, such as from Saudi Arabia, may not significantly impact financials until 2026.
Good afternoon, everyone. As a reminder, Biotricity's fourth quarter and fiscal year 2025 ended on March 31, 2025. So all figures presented for this period will reflect that end date. Earlier, Biotricity issued its earnings press release for the period, which highlighted financial and operational results.
A copy of the press release is available on the investor relations section of the Biotricity website. And the full financials have been filed with SEC on Form 10-K and posted on EDGAR at www.sec.gov.
Before beginning the company's formal remarks, I would like to remind listeners that today's discussion may contain forward-looking statements that reflect management's current views with respect to future events. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements.
Biotricity does not undertake to update any forward-looking statements except required. At this point, I am pleased to turn the call over to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
